How big is BioXcel Therapeutics, Inc.?

As of Jun 18, BioXcel Therapeutics, Inc. has a market capitalization of 9.93 million, with net sales of 1.85 million and a net profit of -40.06 million over the last four quarters. The company's shareholder's funds were -93.10 million, and total assets amounted to 38.34 million.

Market Cap: As of Jun 18, BioXcel Therapeutics, Inc. has a market capitalization of 9.93 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 1.85 million and a net profit of -40.06 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds were -93.10 million, and total assets amounted to 38.34 million.

What does BioXcel Therapeutics, Inc. do?

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs for psychiatric disorders and rare cancers. As of March 2025, it has a market cap of $9.93 million, with net sales of $0 million and a net profit of -$7 million.

Overview: <BR>BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing drugs for psychiatric disorders and rare cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 9.93 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.83 <BR>Return on Equity: 39.44% <BR>Price to Book: -0.11<BR><BR>Contact Details: <BR>Address: 555 Long Wharf Dr, NEW HAVEN CT: 06511-6107 <BR>Tel: ['1 203 6438060', '1 646 3782942'] <BR>Fax: 1 302 6365454 <BR>Website: http://www.bioxceltherapeutics.com/

Should I buy, sell or hold BioXcel Therapeutics, Inc.?

Who are in the management team of BioXcel Therapeutics, Inc.?

As of March 2022, the management team of BioXcel Therapeutics, Inc. includes Dr. Peter Mueller (Independent Chairman), Mr. Vimal Mehta (President, CEO, Co-Founder), Dr. Krishnan Nandabalan (Co-Founder, Chief Digital Officer), and independent directors Dr. Sandeep Laumas and Dr. Michal Votruba. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of BioXcel Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Peter Mueller, who serves as the Independent Chairman of the Board.<BR>- Mr. Vimal Mehta, who is the President, Chief Executive Officer, Co-Founder, Secretary, and Director.<BR>- Dr. Krishnan Nandabalan, who is a Co-Founder, Director, and Chief Digital Officer.<BR>- Dr. Sandeep Laumas, who is an Independent Director.<BR>- Dr. Michal Votruba, who is also an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Is BioXcel Therapeutics, Inc. overvalued or undervalued?

As of August 12, 2025, BioXcel Therapeutics, Inc. is considered overvalued and in financial distress, with poor metrics compared to peers and a year-to-date stock return of -49.69%, significantly underperforming the S&P 500's gain of 12.22%.

As of 12 August 2025, the valuation grade for BioXcel Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is overvalued given its current metrics, particularly with a Price to Book Value of -0.12, an EV to EBIT of -1.74, and an EV to EBITDA of -1.75, all of which suggest severe financial distress and negative returns on capital employed. <BR><BR>In comparison to its peers, C4 Therapeutics, Inc. has a P/E of -1.7285 and an EV to EBITDA of 0.1350, while Champions Oncology, Inc. stands out with a very attractive P/E of 19.9287 and an EV to EBITDA of 13.1831, highlighting how BioXcel's metrics fall short against more stable companies in the sector. Additionally, the company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -49.69% compared to the index's gain of 12.22%, reinforcing the notion that BioXcel is currently overvalued.

Is BioXcel Therapeutics, Inc. technically bullish or bearish?

As of September 9, 2025, BioXcel Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators and significant underperformance compared to the S&P 500, reflecting a year-to-date return of -49.69% versus the S&P 500's 12.22%.

As of 9 September 2025, the technical trend for BioXcel Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is also mildly bullish, indicating some mixed signals. The daily moving averages are mildly bullish, while the weekly Dow Theory shows a mildly bearish stance. The Bollinger Bands present a mildly bullish signal on the weekly but bearish on the monthly, and the KST is bullish weekly but only mildly bullish monthly. The OBV is mildly bearish on the weekly timeframe.<BR><BR>In terms of performance, BioXcel has significantly underperformed compared to the S&P 500 across all periods, with a year-to-date return of -49.69% versus the S&P 500's 12.22%, and a one-year return of -70.48% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven by the mixed indicators and significant underperformance relative to the benchmark.